Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation

Table 4 Comparison of lymphocyte subsets in the recipients between ischemic-type biliary lesion and non- ischemic-type biliary lesion groups

	ITBL group (n = 4)	Non-ITBL group (n = 23)	P value
At patient's admission (Lф -1)
WBC counts (/μL)	3750.0 ± 1658.3	4213.0 ± 2015.5	0.767
Lymphocyte counts (/μL)	1075.0 ± 471.7	965.2 ± 527.1	0.531
B-cell counts (/μL)	197.5 ± 121.5	140.6 ± 106.9	0.336
T-cell counts (/μL)	647.0 ± 300.9	675.3 ± 387.6	0.818
T4/T8 ratio	2.5 ± 0.6	2.2 ± 1.3	0.272
NK cell counts (/μL)	182.3 ± 98.7	100.0 ± 64.5	0.069
After the administration of rituximab (Lф -2)
WBC counts (/μL)	4500.0 ± 3213.5	4234.8 ± 2177.1	0.921
Lymphocyte counts (/μL)	887.5 ± 480.2	739.1 ± 428.3	0.576
T-cell counts (/μL)	646.7 ± 500.8	574.5 ± 267.9	0.974
T4/T8 ratio	2.1 ± 0.5	1.9 ± 0.7	0.974
NK cell counts (/μL)	158.7 ± 71.5	77.6 ± 59.2	0.034
After the transplantation (Lф -3)
WBC counts (/μL)	8800.0 ± 2412.5	8500.0 ± 6925.1	0.448
Lymphocyte counts (/μL)	687.5 ± 243.9	700.0 ± 342.5	0.974
T-cell counts (/μL)	429.0 ± 213.1	575.9 ± 320.4	0.448
T4/T8 ratio	1.3 ± 0.4	2.5 ± 2.8	0.111
NK cell counts (/μL)	170.0 ± 98.2	76.0 ± 63.7	0.027

ABO-I ALDLT: ABO-incompatible adult living donor liver transplantation; ITBL: Ischemic-type biliary lesion; WBC: White blood cell; NK cell: Natural killer cell.